PO , Take after or with meals.

Adult

Alzheimer's dementia: 1.5 mg BID initially, if well tolerated, the dose may be increased to 3 mg BID after a minimum of 2 wks; subsequent increases to 4.5 mg BID and 6 mg BID should be attempted after a minimum of 2 wks at the previous dose. Max. 12mg/d.

Pediatric

Safety and efficacy in children have not been established .

M: Diarrhea/constipation, nausea, vomiting, flatulence, loss of appetite, indigestion, abdominal pain; weight loss; dizziness, tremor, asthenia; UTI.

L or R: hypertension; influenza-like illness.

1.經神經科或精神科醫師依NINDS-ADRDA或DSM或ICD標準診斷為輕度至中度之失智症（MMSE 10~26分或CDR 1級及2級）患者使用。並檢附MMSE或CDR智能測驗結果。

2.使用後每六個月需重新評估，追蹤MMSE或CDR智能測驗，如MMSE較起步治療時減少2分(不含)以上或CDR退步1級，則應停用。

3.如有腦中風病史，臨床診斷為「血管性失智症」，或有嚴重心臟傳導阻斷（heart block）之病患，不建議使用。

4.需經事前審查核准後使用，第一次申請需檢附以下資料：

(1)CT、MRI或哈金斯氏量表（Hachinskki lschemic Scale）三項其中之任一結果報告。

(2)CBC,VDRL,BUN,Scr,GOT,GPT,T4,TSH檢驗。

(3)病歷摘要。

(4)阿茲海默氏症診斷準則。（ 95/6/1 ）

(5)MMSE或CDR智能測驗報告。